These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9890012)

  • 21. Modulating dendritic cells to optimize mucosal immunization protocols.
    Williamson E; Westrich GM; Viney JL
    J Immunol; 1999 Oct; 163(7):3668-75. PubMed ID: 10490961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating cellular immune response to oral immunization of humans with cholera toxin B-subunit.
    Lewis DJ; Castello-Branco LR; Novotny P; Dougan G; Poulton TA; Griffin GE
    Vaccine; 1993; 11(2):119-21. PubMed ID: 8438610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current status of an oral B subunit whole cell cholera vaccine.
    Svennerholm AM; Jertborn M; Gothefors L; Karim A; Sack DA; Holmgren J
    Dev Biol Stand; 1983; 53():73-9. PubMed ID: 6873479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin.
    Lycke N; Holmgren J
    Scand J Immunol; 1986 May; 23(5):611-6. PubMed ID: 3704560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intramuscular delivery of a cholera DNA vaccine primes both systemic and mucosal protective antibody responses against cholera.
    Xu G; Wang S; Zhuang L; Hackett A; Gu L; Zhang L; Zhang C; Wang H; Huang Z; Lu S
    Vaccine; 2009 Jun; 27(29):3821-30. PubMed ID: 19443090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral immunization induces local and distant mucosal immunity in swine.
    Hyland K; Foss DL; Johnson CR; Murtaugh MP
    Vet Immunol Immunopathol; 2004 Dec; 102(3):329-38. PubMed ID: 15507316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucosal immunization with recombinant MOMP genetically linked with modified cholera toxin confers protection against Chlamydia trachomatis infection.
    Singh SR; Hulett K; Pillai SR; Dennis VA; Oh MK; Scissum-Gunn K
    Vaccine; 2006 Feb; 24(8):1213-24. PubMed ID: 16194585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of a local and systemic immune response using cholera toxin as vehicle to deliver antigen in the lamina propria of the chicken intestine.
    Vervelde L; Janse EM; Vermeulen AN; Jeurissen SH
    Vet Immunol Immunopathol; 1998 Apr; 62(3):261-72. PubMed ID: 9643459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response.
    McKenzie SJ; Halsey JF
    J Immunol; 1984 Oct; 133(4):1818-24. PubMed ID: 6470484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral vaccine models: multiple delivery systems employing tetanus toxoid.
    Jackson RJ; Staats HF; Xu-Amano J; Takahashi I; Kiyono H; Hudson ME; Gilley RM; Chatfield SN; McGhee JR
    Ann N Y Acad Sci; 1994 Aug; 730():217-34. PubMed ID: 8080173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation of HIV-envelope protein with lipid vesicles expressing ganglioside GM1 associated to cholera toxin B enhances mucosal immune responses.
    Lian T; Bui T; Ho RJ
    Vaccine; 1999 Nov; 18(7-8):604-11. PubMed ID: 10547418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36 months of age.
    Qadri F; Ahmed T; Ahmed F; Bradley Sack R; Sack DA; Svennerholm AM
    Vaccine; 2003 Jun; 21(19-20):2394-403. PubMed ID: 12744870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine.
    Pascual DW; Powell RJ; Lewis GK; Hone DM
    Behring Inst Mitt; 1997 Feb; (98):143-52. PubMed ID: 9382735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization.
    de Geus B; Dol-Bosman M; Scholten JW; Stok W; Bianchi A
    Vaccine; 1997 Jul; 15(10):1110-3. PubMed ID: 9269054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The colon and rectum as inductor sites for local and distant mucosal immunity.
    Haneberg B; Kendall D; Amerongen HM; Apter FM; Neutra MR
    Adv Exp Med Biol; 1995; 371A():107-9. PubMed ID: 8525883
    [No Abstract]   [Full Text] [Related]  

  • 38. Presence of antigen-specific long-term memory cells in systemic lymphoid tissues as well as locally in the gut lamina propria following oral immunization with cholera toxin adjuvant.
    Vajdy M; Lycke N
    Adv Exp Med Biol; 1995; 371B():1495-500. PubMed ID: 7502844
    [No Abstract]   [Full Text] [Related]  

  • 39. Heteropentameric cholera toxin B subunit chimeric molecules genetically fused to a vaccine antigen induce systemic and mucosal immune responses: a potential new strategy to target recombinant vaccine antigens to mucosal immune systems.
    Harakuni T; Sugawa H; Komesu A; Tadano M; Arakawa T
    Infect Immun; 2005 Sep; 73(9):5654-65. PubMed ID: 16113283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific mucosal immunity and enhanced nasopharyngeal clearance of nontypeable Haemophilus influenzae after intranasal immunization with outer membrane protein P6 and cholera toxin.
    Hotomi M; Saito T; Yamanaka N
    Vaccine; 1998 Dec; 16(20):1950-6. PubMed ID: 9796049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.